Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Not listed No phase listed Observational Accepts healthy volunteers

OctavaPink for Women With Dense Breast After Negative Mammography

ClinicalTrials.gov ID: NCT02209389

Public ClinicalTrials.gov record NCT02209389. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 4:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

OctavaPink® For Dense Breast After Negative Mammography

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The OctavaPink test is indicated as an adjunct to mammography for breast cancer screening in asymptomatic women for whom screening or diagnostic mammography findings are normal or benign (BIRADS assessment category 1 or 2) and breast tissue is dense (BIRADS composition/density 3 or 4). The device is intended to increase breast cancer detection in the described patient population. Based upon the result of OctavaPink, the patient will be further evaluated by their physician.

Study identification

NCT ID
NCT02209389
Recruitment status
Not listed
Study type
Observational
Phase
Not listed
Lead sponsor
Eventus Diagnostics Ltd
Industry
Enrollment
1,750 participants

Conditions and interventions

Conditions

Interventions

Device

Eligibility (public fields only)

Age range
30 Years to 79 Years
Sex
Female
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 2014 (Type not available)
Primary completion
Aug 2015 (Estimated)
Completion
Aug 2017 (Estimated)
Last update posted
Aug 19, 2014

2014 – 2017

United States locations

U.S. sites
2
U.S. states
2
U.S. cities
2
Facility City State ZIP Site status
Detroit Clinical Research Center Detroit Michigan 48201 —
MD Anderson cancer center Houston Texas 77030 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02209389, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 19, 2014 · Synced Oct 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02209389 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →